Sentences with phrase «cell lymphoma program»
The Penn team, in collaboration with Alain Rook, MD, director of the Cutaneous T - cell Lymphoma Program and a professor of Dermatology, aims to develop a molecular taxonomy for mutations in SS patients.
https://www.sciencedaily.com/ Not exact matches
A specialist in leukemia, lymphoma, and blood and marrow transplantation, Dr. Collins leads the Hematologic Malignancies / Blood and Marrow Transplantation Program and the combined Adult / Pediatric Stem Cell Transplant Program at UT Southwestern Medical Center.
We are part of a National Cancer Institute - funded Specialized Programs of Research Excellence (SPORE) grant and participate in Children's Oncology Group and internal lymphoma studies within Texas Children's Cancer Center and the Cell and Gene Therapy Program.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
In this Cancer.net video, Sonali M. Smith, MD, director of the lymphoma program, provides an introduction to bone marrow / stem cell transplantation.
This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.
A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma Lymphoma Program.